Research location
Leuven
Vlaams-Brabant, Belgium
Advertisement
Research activity in Leuven
Vlaams-Brabant, BelgiumCureCurrent currently publishes aggregate city-level research activity for this location: 111 trials and 112 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Leuven
102 linked trials · page 1 of 3A Study Comparing an Investigational Wound Gel With Standard Treatment for Mild to Moderate Diabetic Foot UlcersNCT07783087 · 2026-08-10 · 1 site observation
RECRUITING
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)NCT07318597 · 2026-05-06 · 1 site observation
RECRUITING
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497 · 2026-03-16 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510 · 2026-03-12 · 1 site observation
RECRUITING
A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in BelgiumNCT07382440 · 2026-03-09 · 1 site observation
RECRUITING
LFP-based Parameter Prediction in DBS for Parkinson's DiseaseNCT07485621 · 2026-03-05 · 1 site observation
RECRUITING
Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic DisordersNCT07509125 · 2026-02-13 · 1 site observation
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)NCT07216703 · 2026-01-19 · 1 site observation
RECRUITING
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07155187 · 2025-12-10 · 1 site observation
RECRUITING
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07005102 · 2025-08-03 · 1 site observation
RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)NCT07033494 · 2025-07-16 · 1 site observation
RECRUITING
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22 · 1 site observation
RECRUITING
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)NCT06875310 · 2025-04-24 · 1 site observation
RECRUITING
Naltrexone/Bupropion With or Without Very Low Calorie Ketogenic Diet for Weight Regain After Bariatric SurgeryNCT06881485 · 2025-01-20 · 1 site observation
RECRUITING
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)NCT06351592 · 2024-08-28 · 1 site observation
RECRUITING
EUS-guided Response Assessment to NSBBNCT06513195 · 2024-07-17 · 1 site observation
RECRUITING
Who and Why do Patients Report Lymphedema After Breast Cancer Treatment Without an Objective Measurable SwellingNCT06324721 · 2024-03-26 · 1 site observation
RECRUITING
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. ADNCT06120049 · 2024-01-19 · 1 site observation
RECRUITING
Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid ArthritisNCT06003283 · 2024-01-09 · 2 site observations
RECRUITING
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)NCT05714085 · 2023-05-31 · 1 site observation
RECRUITING
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)NCT07218029 · 2021-05-12 · 1 site observation
RECRUITING
Prospective Prostate Cancer and Patient-reported Outcomes RegistryNCT04694924 · 2020-10-01 · 1 site observation
RECRUITING
The Influence of Chemotherapy on Position SenseNCT07367711 · 2026-02-01 · 1 site observation
NOT_YET_RECRUITING
Untreated Parkinson's Disease Work-up Assessing Resident Microbiota and Duodenal Barrier FunctionNCT07418658 · 2026-02-01 · 1 site observation
NOT_YET_RECRUITING
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.NCT07595666 · 2025-09-30 · 1 site observation
ENROLLING_BY_INVITATION
Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung CancerNCT07259447 · 2024-06-21 · 1 site observation
ACTIVE_NOT_RECRUITING
The Impact of a Moderate Carbohydrate Diet in Children With Type 1 Diabetes on Hybrid Closed-loop TherapyNCT06567158 · 2024-05-15 · 1 site observation
UNKNOWN
Radioembolisation and Chemotherapy in Liver Metastatic Breast Cancer PatientsNCT06142344 · 2023-10-19 · 1 site observation
UNKNOWN
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)NCT05869955 · 2023-09-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPDNCT05612035 · 2023-03-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Prevalence of Glaucoma in Belgium: a Multicenter National TrialNCT05703724 · 2023-03-08 · 1 site observation
COMPLETED
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)NCT05665595 · 2023-01-19 · 1 site observation
TERMINATED
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)NCT05564039 · 2022-11-30 · 1 site observation
COMPLETED
DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte MaturationNCT04616729 · 2022-11-01 · 1 site observation
UNKNOWN
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)NCT05508867 · 2022-10-18 · 1 site observation
COMPLETED
Left Bundle Branch Area Pacing Using Conventional Stylet-driven Pacemaker Leads for Cardiac Resynchronization TherapyNCT05365568 · 2022-09-01 · 1 site observation
ACTIVE_NOT_RECRUITING
The Use of a Monitoring Device by General Practitioners During Out-of-hours CareNCT05222711 · 2022-05-01 · 1 site observation
UNKNOWN
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)NCT04811092 · 2022-03-18 · 1 site observation
TERMINATED
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)NCT04945460 · 2021-12-29 · 1 site observation
COMPLETED
Maternal Treatment With ACE-inhibitors and Breastfeeding: a Mono-centric Study on the Exposure Through Breast MilkNCT06088849 · 2021-12-20 · 1 site observation
COMPLETED
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).NCT05116189 · 2021-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)NCT04896008 · 2021-12-01 · 1 site observation
COMPLETED
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerNCT04975308 · 2021-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Investigating Multimodally Endothelial Dysfunction in Ocular and Systemic DiseaseNCT06485128 · 2021-07-06 · 1 site observation
UNKNOWN
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).NCT04895722 · 2021-06-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)NCT04732221 · 2021-05-19 · 1 site observation
COMPLETED
The Prevalence of Foot Complaints/Problems and Ulcers in a Pre-dialysis PopulationNCT04784650 · 2021-01-31 · 1 site observation
COMPLETED
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)NCT04576988 · 2021-01-25 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)NCT04634877 · 2021-01-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)NCT04662710 · 2020-12-30 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.